Advertisement
Canada markets close in 1 hour 13 minutes

  • S&P/TSX

    21,637.22
    -18.83 (-0.09%)
     

  • S&P 500

    5,008.47
    -13.74 (-0.27%)
     

  • DOW

    37,750.19
    -3.12 (-0.01%)
     

  • CAD/USD

    0.7261
    -0.0002 (-0.03%)
     

  • CRUDE OIL

    82.70
    +0.01 (+0.01%)
     

  • Bitcoin CAD

    87,054.23
    +1,916.95 (+2.25%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • GOLD FUTURES

    2,395.30
    +6.90 (+0.29%)
     

  • RUSSELL 2000

    1,943.12
    -4.82 (-0.25%)
     

  • 10-Yr Bond

    4.6430
    +0.0580 (+1.26%)
     

  • NASDAQ

    15,602.89
    -80.48 (-0.51%)
     

  • VOLATILITY

    18.13
    -0.08 (-0.44%)
     

  • FTSE

    7,877.05
    +29.06 (+0.37%)
     

  • NIKKEI 225

    38,079.70
    +117.90 (+0.31%)
     

  • CAD/EUR

    0.6817
    +0.0015 (+0.22%)
     
MARKETS LIVE BLOG:

STOCKS RISE AS TECHS REVIVE, WITH NETFLIX EARNINGS ON TAP

Tesla shares slide to 52-week low; stock is down roughly 40% year-to-date

J&J eyes September for late-stage study of potential COVID-19 vaccine

Reuters
·1 min read
FILE PHOTO: The Johnson & Johnson logo is displayed on a screen on the floor of the NYSE in New York

(Reuters) - Johnson & Johnson said on Thursday it was in talks to begin late-stage studies of its experimental coronavirus vaccine in September.

"We are in discussions with the National Institute of Health with the objective to start the Phase III clinical trial ahead of its original schedule, potentially in late September," J&J Chief Scientific Officer Paul Stoffels said.

The company is on track to begin its early-stage human trial of the vaccine later this month, expected to begin in Belgium on July 22, Stoffels said on a post-earnings conference call.

(The story is refiled to correct key word search for media clients)

(Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)